TEER for Severe DMR of Low to Intermediate Surgery Risk
Key facts
- Who runs it
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 160 people, planned
- Started
- 1 Jan 2024
- Expected to end
- Dec 2026
- Type of study
- Observational
- Treatments tested
- ultrasonic cardiography (UCG)
- TEER
- Record updated
- 15 March 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (36)Hide the full registry criteria
Who can take part
- age ≥ 18 years old
- DMR ≥ grade 3+ according to UCG integrative approach, referring to the following quantitative indicators: 1) effective regurgitant orifice area (EROA) ≥0.3cm\^2; 2) regurgitant volume (RVol) ≥45ml; 3) regurgitant fraction (RF) ≥40%
- symptomatic heart failure ( New York Heart Association (NYHA) class II-IV ), or asymptomatic heart failure with left ventricular end systolic dimension (LVESd) ≥40mm or ejection fraction (EF) ≤60%, or new-onset atrial fibrillation, or resting pulmonary artery systolic pressure (PASP) >50mmHg
- The patient with American Association of Thoracic Surgeons Score (STS) <8 has surgical indications evaluated by cardiac team
- The patient has signed an informed consent form and agreed to regular follow-up for at least 1 year
Who cannot take part
- inability to tolerate intraoperative or postoperative antithrombotic (anticoagulant or antiplate) therapy
- acute myocardial infarction within 4 weeks before operation
- acute cerebrovascular accident within 30 days before operation
- acute peptic ulcer or upper gastrointestinal bleeding within 3 months before operation
- The patient is participating in an experimental drug or other device study with an incomplete primary endpoint, or the patient is participating in an unfinished experimental drug or other device study that would clinically interfere with our study endpoints
- active infective endocarditis especially occurring in the mitral valve area, or mitral valve perforation
- rheumatic mitral valve disease, mitral stenosis or mitral valve orifice area < 4mm\^2
- combined valve lesions requiring surgery, e.g. severe tricuspid regurgitation or aortic valve disease
- the present of tumour, thrombus or redundant organisms in the heart chambers
- Due to the presence of certain anatomical conditions, patient has a low success rate for TEER assessed by the operator and is not appropriate for enrolment. The conditions include but are not limited to the followings: 1) the venous approach is not suitable for operation, such as thrombus in the approach and small vein diameter; 2) severe calcification presents in the flap leaflet clamping area; 3) mitral valve cleft; 4) multiple regurgitant flow, especially in the internal and external union junction area; 5) Barlow disease; 6) leaflet length <7mm; 7) flail gap >10mm; 8) flail width >15mm
- proposed implantation of heart failure device such as cardiac resynchronization therapy/cardiac resynchronization therapy defibrillator (CRT/CRT-D) or cardiac contractility modulation (CCM)
- untreated severe coronary artery stenosis requiring coronary revascularization, or other cardiac macrovascular disease requiring surgery
- hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or structural heart disease leading to heart failure other than dilated heart disease
- severe pulmonary hypertension ( PASP >70 mmHg), or pulmonary hypertension associated with no-left heart disease, e.g. pulmonary arterial hypertension (PAH) etc
- uncontrolled autoimmune connective tissue diseases especially Behcet's disease and systemic lupus erythematosus (SLE)
- severe infections, septicaemia
- severe hepatic insufficiency, e.g. acute severe hepatitis, decompensated cirrhosis ( Child-Pugh class C)
- contraindication for TEE, e.g. oesophageal constriction, oesophageal tumour, oesophageal fistula, oesophageal varices, cervical vertebral instability, etc
- contraindication for intravenous anaesthesia, e.g. allergy to anaesthetics
- severe cardiac insufficiency ( NYHA class IV or lefr ventricular ejection fraction (LVEF) <20% ), end-stage heart failure status ( American College of Cardiology/American Heart Association (ACC/AHA) Stage D), relying on circulation aids or waiting for heart transplantation
- severe renal insufficiency ( chronic kidney disease (CKD) stage 5: estimated glomerular filtration rate (eGFR) < 15 ml/min or dialysis)
- uncontrolled diseases of the haematological system: acute gastrointestinal bleeding, intracranial haemorrhage or haemorrhage from other organs, acute pulmonary embolism or deep vein thrombosis, congenital or acquired haemorrhagic disease such as haemophilia, anaphylactic purpura and acute leukaemia, severe abnormalities in haematological parameters such as platelet count <20*10\^9/L and international normalized ratio (INR) >3
- acute DMR, e.g. DMR caused by acute papillary muscle rupture
- uncontrolled hyperthyroidism
- amyloidosis
- hypotensive state, shock ( systolic blood pressure < 90mmHg or mean arterial pressure <70 mmHg with tissue hypoperfusion and urine output < 30 ml/h)
- pregnancy or breastfeeding
- The patient does not sign an informed consent form
- expected survival less than 1 year
- The patient with poor compliance is not thought to complete follow-up visits
- Due to other reasons the patient is not suitable for enrollment assessed by the researcher
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Mitral regurgitation
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate the efficacy and safety of transcatheter mitral valve edge-to-edge repair (TEER) for severe degenerative mitral regurgitation (DMR) patients of low to intermediate surgery risk.
The group in the trial
- TEER group
Severe DMR patients of low to intermediate surgery risk who underwent TEER.
Treatment: ultrasonic cardiography (UCG) and TEER
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Efficacy and Safety of TEER for Severe DMR Patients of Low to Intermediate Surgery Risk (TESLA-R)--a Multi-center, Prospective Cohort Study
- Criteria questions
- Built from NCT06162780, who can take part
- Record updated
- 15 March 2024